HDAC8 and neuroblastoma: In summary, we conclude that targeting ALK diminishes HDAC8 inhibitor treatment-mediated neuroblastoma cell differentiation and cell cycle arrest and inhibits ERK signaling, shifting the phenotype toward efficient neuroblastoma cell death and HDAC8 inhibition affects expression of ALK targets, such as RET (model Fig. 7g).